SS Innovations International, Inc. (NASDAQ: SSII), a developer of surgical robotic technologies, announced on October 5, 2026, that it submitted its response to the U.S. Food and Drug Administration's (FDA) request for additional information regarding its 510(k) submission for the SSi Mantra surgical robotic system. The response includes final data from an expanded human clinical and human factors validation study, as well as a bridging study completed in August 2026 at Hospital Internacional de Colombia, a member of the Mayo Clinic Care Network. The submission covers the initial indication of cholecystectomy, or gallbladder removal.
The company anticipates that the FDA will complete its review of the response and 510(k) submission in the first quarter of 2027. This regulatory milestone is critical for SS Innovations as it seeks to introduce the SSi Mantra system to the U.S. market, which is the world's largest market for surgical robotics. The U.S. market is currently dominated by Intuitive Surgical's da Vinci system, and the entry of a cost-effective alternative could disrupt the competitive landscape, potentially lowering costs and expanding access to robotic-assisted surgery for a broader patient population.
SS Innovations is focused on making robotic surgery affordable and accessible globally. The SSi Mantra system is a modular, multi-arm robotic platform with advanced features such as 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, and the ability to superimpose 3D models of diagnostic imaging. It utilizes over 40 different types of robotic endo-surgical instruments, including 5mm instruments for pediatric and ENT surgeries. The system has been clinically validated in India in more than 190 different types of surgical procedures, demonstrating its versatility and potential to support a wide range of specialties, including cardiac surgery.
The FDA's clearance of the SSi Mantra for cholecystectomy would mark a significant step toward broader adoption in the U.S. If cleared, the company plans to expand indications to other procedures. The successful entry into the U.S. market could also accelerate the company's growth trajectory, enhance its credibility, and attract further investment. Moreover, it could pressure competitors to innovate and reduce prices, ultimately benefiting patients and healthcare providers.
For investors, the FDA submission and anticipated review timeline represent a key catalyst. The company's progress is closely monitored, and updates are available in its newsroom at https://ibn.fm/SSII. The full press release can be accessed at https://ibn.fm/A6dJ8. SS Innovations, headquartered in India, is a U.S. company with a vision to democratize robotic surgery. Its product range includes the SSi Mantra and the SSi Mudra surgical instruments. More information is available on the company's website at ssinnovations.com and its LinkedIn page.
The announcement was distributed through TechMediaWire, a communications platform focused on technology companies. TechMediaWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, and social media distribution. For full terms of use and disclaimers, visit https://www.TechMediaWire.com/Disclaimer.
